Locations:
Search IconSearch
July 2, 2021/Neurosciences/Podcast

When to Suspect Autoimmune Causes for Neurologic Disorders (Podcast)

Prompt treatment can improve outcomes

The field of autoimmune neurology is rapidly gaining recognition, particularly in regard to patients with status epilepticus and sudden severe neurocognitive or neuropsychiatric changes. However, autoimmune causes often are overlooked in patients with more subtle abnormalities — such as mild to moderate cognitive changes, seizure auras and faciobrachial seizures, says Amy Kunchok, MD, a neurologist who specializes in the field at Cleveland Clinic.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In the newest episode of Cleveland Clinic’s Neuro Pathways podcast, Dr. Kunchok explains more about this nascent subspecialty. She briefly discusses:

  • Progress in understanding the pathogenesis, clinical presentation and treatment of autoimmune encephalitis and other autoimmune neurologic disorders
  • Workup when an autoimmune disorder is suspected
  • How to treat disorders and how soon to begin treatment
  • Prognosis for patients
  • The next frontier in autoimmune neurology research

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.

Excerpt from the podcast

Podcast host Glen Stevens, DO, PhD: Monthly you’ve been running a very interesting neuroimmunology encephalitis conference where we’ve discussed cases on service. There was an interesting case of faciobrachial seizures recently. Can you talk about that disorder a bit?

Dr. Kunchok: We recently discussed anti-LGI1 encephalitis in our case conference, and we talked about faciobrachial dystonic seizures and the clinical presentation — how these seizures may involve even just subtle movements of the hand or arm. These can be dystonic-like movements. They also can involve facial movements. These movements are often subtle at the beginning and can have normal EEG, without an epileptic correlate in some of these cases, which can make it difficult to recognize them. But this is a very pathognomonic finding for anti-LGI1 encephalitis.

Advertisement

A less common phenotype was seen recently in some of our patients with pilomotor seizures, where they basically have goosebumps. One patient we discussed had some bradycardiac episodes as well, which is an interesting phenotype that is less common but also described in anti-LGI1 encephalitis.

**********************************************************************************

Among our current cohort of patients, there are quite a few who have anti-LGI1 encephalitiswho have done very well with steroids. Some of them have additional immunotherapy — for example, rituximab — but they’ve done very well and have improved in their cognition. The faciobrachial dystonic seizures have settled down with immunotherapy, and some patients have even returned to work. I have one patient who returned to work within three months of receiving immunotherapy.

Additionally, with anti-NMDA-R encephalitis — which in some cases can be a severe encephalitis — we have had quite a few patients who have been treated very promptly within the hospital service. Their seizures have settled down, and within a year several young patients returned to study or work. Actually, we have one patient who’s completing a degree at present, only one year after having anti-NMDA-R encephalitis. So there have been some very good outcomes as a result of prompt immunotherapy in the acute setting, probably in addition to some longer-term immunotherapy.

Advertisement

Related Articles

16-NEU-2800-Kubu-101058161-650×450
What Do Patients Want from DBS for Parkinson’s Disease?

New study advances understanding of patient-defined goals

photo of a man sleeping at a desk, with a podcast icon overlay
March 15, 2024/Neurosciences/Podcast
Diagnosis and Management of Idiopathic Hypersomnia (Podcast)

Testing options and therapies are expanding for this poorly understood sleep disorder

illustration of an alzheimer brain and a packet of sildenafil pills
March 11, 2024/Neurosciences/Research
Sildenafil as an Alzheimer’s Candidate Drug: Further Support From Insurance Database and Mechanistic Studies

Real-world claims data and tissue culture studies set the stage for randomized clinical testing

brain scan showing perimesencephalic subarachnoid hemorrhage
Study Supports Less-Strict Monitoring for Nonaneurysmal Perimesencephalic SAH Without Hydrocephalus

Digital subtraction angiography remains central to assessment of ‘benign’ PMSAH

illustrated brain with the letters "AI" on a computer circuit board
As AI Tools Emerge, Be Proactive and Engaged to Shape Their Development

Cleveland Clinic neuromuscular specialist shares insights on AI in his field and beyond

histology image of a gray matter lesion in a multiple sclerosis brain
Study Suggests Protective Role for Microglia at Borders of Gray Matter Lesions in Progressive MS

Findings challenge dogma that microglia are exclusively destructive regardless of location in brain

series of digital-looking brain icons with a podcast button overlay on top
March 1, 2024/Neurosciences/Podcast
Harnessing the Power of AI in Medicine (Podcast)

Neurology is especially well positioned for opportunities to enhance clinical care and medical training

illustration of a neuron affected by multiple sclerosis
Clinical Trials in Progressive MS: An Assessment of Advances and Remaining Challenges

New review distills insights from studies over the past decade

Ad